Update on risk-stratified management for chronic lymphocytic leukemia

Clive S. Zent, Timothy G. Call, William Hogan, Tait D. Shanafelt, Neil Elliot Kay

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Major recent advances in understanding the biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) have improved clinical evaluation and influenced treatment decisions. CLL can be diagnosed early and accurately, and biological measurements can be used to predict a prognosis at diagnosis. Individual patient care can be risk stratified to optimize benefit and minimize complications of therapy. Purine analogs and monoclonal antibodies have markedly improved the efficacy of initial therapy but are not curative. The treatment of relapsed and refractory CLL is less successful. However, recent developments suggest that allogeneic stem cell transplant could have a larger role in a selected group of these patients. Potential new treatment modalities include targeted molecules that interrupt key components of CLL cell survival pathways, and active and passive immunotherapy. The management of CLL is in a dynamic phase of rapid evolution. Risk stratification using biological prognostic markers can improve current patient care and direct future clinical research.

Original languageEnglish (US)
Pages (from-to)1738-1746
Number of pages9
JournalLeukemia and Lymphoma
Volume47
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Risk Management
B-Cell Chronic Lymphocytic Leukemia
Patient Care
Therapeutics
Active Immunotherapy
Passive Immunization
Cell Survival
Stem Cells
Biomarkers
Monoclonal Antibodies
Transplants
Research

Keywords

  • CLL
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Update on risk-stratified management for chronic lymphocytic leukemia. / Zent, Clive S.; Call, Timothy G.; Hogan, William; Shanafelt, Tait D.; Kay, Neil Elliot.

In: Leukemia and Lymphoma, Vol. 47, No. 9, 09.2006, p. 1738-1746.

Research output: Contribution to journalArticle

Zent, Clive S. ; Call, Timothy G. ; Hogan, William ; Shanafelt, Tait D. ; Kay, Neil Elliot. / Update on risk-stratified management for chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2006 ; Vol. 47, No. 9. pp. 1738-1746.
@article{fb974ca83ab148e0b21eee0c48edc5ed,
title = "Update on risk-stratified management for chronic lymphocytic leukemia",
abstract = "Major recent advances in understanding the biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) have improved clinical evaluation and influenced treatment decisions. CLL can be diagnosed early and accurately, and biological measurements can be used to predict a prognosis at diagnosis. Individual patient care can be risk stratified to optimize benefit and minimize complications of therapy. Purine analogs and monoclonal antibodies have markedly improved the efficacy of initial therapy but are not curative. The treatment of relapsed and refractory CLL is less successful. However, recent developments suggest that allogeneic stem cell transplant could have a larger role in a selected group of these patients. Potential new treatment modalities include targeted molecules that interrupt key components of CLL cell survival pathways, and active and passive immunotherapy. The management of CLL is in a dynamic phase of rapid evolution. Risk stratification using biological prognostic markers can improve current patient care and direct future clinical research.",
keywords = "CLL, Prognosis, Therapy",
author = "Zent, {Clive S.} and Call, {Timothy G.} and William Hogan and Shanafelt, {Tait D.} and Kay, {Neil Elliot}",
year = "2006",
month = "9",
doi = "10.1080/10428190600634036",
language = "English (US)",
volume = "47",
pages = "1738--1746",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Update on risk-stratified management for chronic lymphocytic leukemia

AU - Zent, Clive S.

AU - Call, Timothy G.

AU - Hogan, William

AU - Shanafelt, Tait D.

AU - Kay, Neil Elliot

PY - 2006/9

Y1 - 2006/9

N2 - Major recent advances in understanding the biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) have improved clinical evaluation and influenced treatment decisions. CLL can be diagnosed early and accurately, and biological measurements can be used to predict a prognosis at diagnosis. Individual patient care can be risk stratified to optimize benefit and minimize complications of therapy. Purine analogs and monoclonal antibodies have markedly improved the efficacy of initial therapy but are not curative. The treatment of relapsed and refractory CLL is less successful. However, recent developments suggest that allogeneic stem cell transplant could have a larger role in a selected group of these patients. Potential new treatment modalities include targeted molecules that interrupt key components of CLL cell survival pathways, and active and passive immunotherapy. The management of CLL is in a dynamic phase of rapid evolution. Risk stratification using biological prognostic markers can improve current patient care and direct future clinical research.

AB - Major recent advances in understanding the biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) have improved clinical evaluation and influenced treatment decisions. CLL can be diagnosed early and accurately, and biological measurements can be used to predict a prognosis at diagnosis. Individual patient care can be risk stratified to optimize benefit and minimize complications of therapy. Purine analogs and monoclonal antibodies have markedly improved the efficacy of initial therapy but are not curative. The treatment of relapsed and refractory CLL is less successful. However, recent developments suggest that allogeneic stem cell transplant could have a larger role in a selected group of these patients. Potential new treatment modalities include targeted molecules that interrupt key components of CLL cell survival pathways, and active and passive immunotherapy. The management of CLL is in a dynamic phase of rapid evolution. Risk stratification using biological prognostic markers can improve current patient care and direct future clinical research.

KW - CLL

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33750476694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750476694&partnerID=8YFLogxK

U2 - 10.1080/10428190600634036

DO - 10.1080/10428190600634036

M3 - Article

VL - 47

SP - 1738

EP - 1746

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -